Latest News for: jnj

Edit

Final Trade: CME, JNJ, AFRM, WMT

CNBC 03 Apr 2026
The final trades of the day with the 'Fast Money' traders ... .
Edit

JNJ Stock’s 60% Breakout: Why Wall Street is Torn (Insight Guru Inc)

Public Technologies 02 Apr 2026
) JNJ Stock's 60% Breakout ... JNJ ... Johnson & Johnson (JNJ) stock is up 62% over the last twelve months ... JNJ stock has strong momentum ... Why Bet On JNJ Now? ... The big question for JNJ investors right now is this.
Edit

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 ...

The Daily Record - Dunn 30 Mar 2026
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March ....
Edit

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer (Form 6-K) (Nanobiotix SA)

Public Technologies 30 Mar 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer ... About JNJ-1900 (NBTXR3). JNJ-1900 (NBTXR3) is a ...
Edit

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

FX Empire 27 Mar 2026
....
Edit

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's ...

The Galveston Daily News 23 Mar 2026
Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology ....
Edit

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers (Tuhura Biosciences Inc)

Public Technologies 23 Mar 2026
"I am confident that his recent leadership role and strategic contributions to JNJ's menin inhibitor, bleximenib in NPM1 mutated AML, will prove invaluable to our ... During his tenure at JNJ, Dr.
Edit

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

PR Newswire 23 Mar 2026
"I am confident that his recent leadership role and strategic contributions to JNJ's menin inhibitor, bleximenib in NPM1 mutated AML, will prove invaluable to our regulatory pathway and development of TBS-2025 in AML and other blood related cancers.
Edit

Final Trade: JNJ, MOS, XLE

CNBC 12 Mar 2026
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders ... .
Edit

Even after their runs, JNJ, MRK and AMGN aren't expensive: Jim Cramer

CNBC 05 Feb 2026
CNBC's Jim Cramer discusses the day's market action, the potential impact of AI and Anthropic's Claude, what it will take for legacy tech companies to trade higher and more ... .
Edit

JNJ stock price today: Why Johnson & Johnson shares dropped despite strong 2026 forecast? Here's what inve

The Times of India 21 Jan 2026
JNJ stock price today ... .
Edit

JNJ stock price today: Why Johnson & Johnson shares dropped despite strong 2026 forecast? Here's ...

The Economic Times 21 Jan 2026
JNJ stock price today ... The company remains optimistic about its future portfolio. .
  • 1

Article Search

tools
×
×
×
×